ROCO:4186'
s Quick Ratio Range Over the Past 10 Years
Min: 0.51 Med: 0.89 Max: 1.49
Current: 0.9
During the past 13 years, Taiwan Advance Bio-Pharmaceutical's highest Quick Ratio was 1.49. The lowest was 0.51. And the median was 0.89.
ROCO:4186's Quick Ratio is ranked worse than 82.57% of 1411
companies
in the Biotechnology industry
Industry Median: 3.6
vs ROCO:4186: 0.90
Taiwan Advance Bio-Pharmaceutical (ROCO:4186) Quick Ratio Explanation
The quick ratio is more conservative than the Current Ratio because it excludes inventories from current assets. The ratio derives its name presumably from the fact that assets such as cash and marketable securities are quick sources of cash. Inventories generally take time to be converted into cash, and if they have to be sold quickly, the company may have to accept a lower price than book value of these inventories. As a result, they are justifiably excluded from assets that are ready sources of immediate cash.
In general, low or decreasing quick ratios generally suggest that a company is over-leveraged, struggling to maintain or grow sales, paying bills too quickly or collecting receivables too slowly. On the other hand, a high or increasing quick ratio generally indicates that a company is experiencing solid top-line growth, quickly converting receivables into cash, and easily able to cover its financial obligations. Such companies often have faster inventory turnover and cash conversion cycles.
The higher the quick ratio, the better the company's liquidity position.
Taiwan Advance Bio-Pharmaceutical Quick Ratio Related Terms
Taiwan Advance Bio-Pharmaceutical Quick Ratio Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Taiwan Advance Bio-Pharmaceutical Quick Ratio Chart
ROCO:4186 vs VRTX, REGN, ALNY: Quick Ratio Comparison
For the Biotechnology subindustry, Taiwan Advance Bio-Pharmaceutical's Quick Ratio, along with its competitors' market caps and Quick Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Taiwan Advance Bio-Pharmaceutical Quick Ratio vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Taiwan Advance Bio-Pharmaceutical's Quick Ratio distribution charts can be found below:
* The bar in red indicates where Taiwan Advance Bio-Pharmaceutical's Quick Ratio falls into.
Taiwan Advance Bio-Pharmaceutical Quick Ratio Calculation
The quick ratio measures a company's ability to meet its short-term obligations with its most liquid assets. For this reason, the ratio excludes inventories from current assets.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Taiwan Advance Bio-Pharmaceutical (ROCO:4186) has a Quick Ratio of 0.90 as of Dec. 2025. Quick ratio is the ratio of current assets less inventory to current liabilities. View historical data on Taiwan Advance Bio-Pharmaceutical and its competitors. This is near median its historical median of 0.89. Over the past decade, Taiwan Advance Bio-Pharmaceutical's Quick Ratio has ranged from 0.51 to 1.49. According to the industry distribution chart, Taiwan Advance Bio-Pharmaceutical ranks #1165 out of 1411 companies in the Biotechnology industry, placing it in the top 82.6%.
Is Taiwan Advance Bio-Pharmaceutical's Quick Ratio too high?
Taiwan Advance Bio-Pharmaceutical's current Quick Ratio of 0.90 is near median its 10-year median of 0.89. Over the past 10 years, this metric has ranged from a low of 0.51 to a high of 1.49. The Biotechnology industry median Quick Ratio is 3.60. Taiwan Advance Bio-Pharmaceutical's value of 0.90 is 75% below this industry median. Based on the distribution chart, Taiwan Advance Bio-Pharmaceutical ranks #1165 out of 1411 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, Taiwan Advance Bio-Pharmaceutical has a GF Score™ of 57/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Taiwan Advance Bio-Pharmaceutical's Quick Ratio compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Taiwan Advance Bio-Pharmaceutical ranks #1165 out of 1411 companies for Quick Ratio. This places Taiwan Advance Bio-Pharmaceutical in the lower half of its industry. The industry median Quick Ratio is 3.60. Taiwan Advance Bio-Pharmaceutical's value of 0.90 is 75% below this benchmark. Historically, Taiwan Advance Bio-Pharmaceutical's own Quick Ratio has ranged from 0.51 to 1.49 over the past decade. While the company's 10-year median is 0.89 vs. the industry median of 3.60, Taiwan Advance Bio-Pharmaceutical has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Quick Ratio for a Biotechnology company?
The median Quick Ratio among Biotechnology companies is 3.60, based on 1,411 companies in the industry. Companies in the top quartile (top 25%) have a Quick Ratio significantly above this median, while those in the bottom quartile fall well below. However, Quick Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Taiwan Advance Bio-Pharmaceutical's current Quick Ratio of 0.90 is 75% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Quick Ratio mean?
A high Quick Ratio can signal that a stock is expensive relative to its fundamentals. Quick ratio is the ratio of current assets less inventory to current liabilities. View historical data on Taiwan Advance Bio-Pharmaceutical and its competitors. For the Biotechnology industry, the median Quick Ratio is 3.60 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Taiwan Advance Bio-Pharmaceutical's current Quick Ratio is 0.90, which is near median its own 10-year median of 0.89. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Taiwan Advance Bio-Pharmaceutical stock overvalued right now?
Based on GuruFocus' analysis, Taiwan Advance Bio-Pharmaceutical (ROCO:4186) is currently considered Possible Value Trap. The stock's GF Value™ is NT$17.88, compared to a current price of NT$10.10 — trading 43.5% below its estimated fair value. The current Quick Ratio is 0.90, which is near median its 10-year median of 0.89 and 75% below the Biotechnology industry median of 3.60. Taiwan Advance Bio-Pharmaceutical's overall GF Score™ is 57/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Quick Ratio calculated?
Quick Ratio is calculated from a company's financial statements. For Taiwan Advance Bio-Pharmaceutical (ROCO:4186), the current Quick Ratio is 0.90 as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Taiwan Advance Bio-Pharmaceutical (ROCO:4186) Overvalued in 2026?
Based on GuruFocus' analysis, Taiwan Advance Bio-Pharmaceutical stock appears to be undervalued.
The current stock price of NT$10.10 is trading 43.5% below its estimated GF Value™ of NT$17.88.
GuruFocus considers Taiwan Advance Bio-Pharmaceutical to be Possible Value Trap.
Key valuation signals for ROCO:4186:
Quick Ratio: 0.90 (near median its 10-year median of 0.89)
GF Value™: NT$17.88 vs. price of NT$10.10 (43.5% below fair value)
Industry Position: 75% below the Biotechnology median (#1165 of 1411)
No single metric tells the full story. See the ROCO:4186 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Taiwan Advance Bio-Pharmaceutical Business Description
Taiwan Advance Bio-Pharmaceutical Inc operates in the food safety industry. The company's products include a Food safety test kit, Animal test kit, Pesticide test kit, Mycotoxin test kit, Nuleic acid extraction kit.
57GF Score
Get the complete analysis for ROCO:4186
Quick Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ROCO:4186 has been successfully added to your 
